Clinical Scorecard: Prevalence of Legionella Antibodies Among Blood Donors in Northeastern Australia: A Comparative Study from 2016 to 2023
At a Glance
Category
Detail
Condition
Legionellosis including Legionnaires’ disease and Pontiac fever
Key Mechanisms
Inhalation of Legionella bacteria from environmental sources such as water systems (L. pneumophila) and potting soil (L. longbeachae)
Target Population
General population with higher risk in elderly, immunocompromised, smokers, and those with comorbidities
Care Setting
Public health surveillance, clinical diagnosis and management in hospital and community settings
Key Highlights
Total Legionella seroprevalence remained stable (~32%) between 2016 and 2023 in Northeastern Australia.
Decrease in L. pneumophila seropositivity and increase in L. longbeachae seropositivity observed over the study period.
Rainfall and specific land cover types (croplands, urban areas) positively associated with Legionella seropositivity.
Guideline-Based Recommendations
Diagnosis
Use indirect immunofluorescence assays to detect Legionella IgG antibodies for seroprevalence assessment.
Consider species-specific serogroups: L. pneumophila (SG 1–6, 7–14) and L. longbeachae (SG 1 and 2).
Recognize clinical presentation ranging from mild Pontiac fever to severe Legionnaires’ disease pneumonia.
Management
Identify and decontaminate environmental sources such as cooling towers and potting soil to prevent outbreaks.
Prioritize treatment and monitoring of high-risk groups including elderly, immunosuppressed, and those with comorbidities.
Legionnaires’ disease requires prompt antibiotic therapy and supportive care.
Monitoring & Follow-up
Maintain surveillance of Legionella infections as a notifiable condition in Australia.
Monitor environmental factors such as rainfall and land use changes that may influence Legionella prevalence.
Track outbreak clusters and implement rapid public health interventions to control spread.
Risks
Legionella infection is not spread person-to-person but via environmental exposure.
Increased risk in smokers, immunocompromised individuals, and those with chronic diseases.
Legionnaires’ disease has a mortality rate of approximately 10%, higher in vulnerable populations.
Patient & Prescribing Data
Blood donors from Queensland and northeastern New South Wales, representing general adult population
Seroprevalence data indicate exposure trends but do not directly inform individual treatment; clinical management guided by diagnosis and risk factors.
Clinical Best Practices
Assess Legionella exposure risk in patients with pneumonia symptoms, especially in high-risk groups.
Incorporate environmental and demographic risk factors when evaluating potential legionellosis cases.
Use species-specific diagnostic testing to guide public health responses and outbreak investigations.
by Juniper Lethbridge, Wesley Freppel, Mei Fong Ho, Eloise B Skinner, Lina Rustanti, Eileen Roulis, Penny A Rudd, Helen M Faddy, Megan K Young, Lara J Herrero
